Ribonucleic Acid (RNA) Probe Global Market Report 2026

Ribonucleic acid (RNA) probes are short, single-stranded RNA molecules specifically designed to selectively bind with complementary nucleic acid sequences for the detection, identification, or quantification of targeted RNA molecules. These probes are developed with precise nucleotide sequences and are commonly labeled with fluorescent, radioactive, or enzymatic markers to facilitate visualization and analytical detection. They are extensively used in molecular diagnostics and research applications for gene expression studies, pathogen identification, and genetic analysis with high specificity and sensitivity.

The primary product types of ribonucleic acid (RNA) probe include labeled ribonucleic acid probes, radiolabeled ribonucleic acid probes, biotinylated ribonucleic acid probes, digoxigenin-labeled ribonucleic acid probes, chemiluminescent ribonucleic acid probes, and custom or synthesized ribonucleic acid probes. Labeled ribonucleic acid probes refer to RNA molecules attached with detectable markers that are used for the identification and analysis of specific nucleic acid sequences. These products utilize technologies such as in situ hybridization, fluorescence in situ hybridization, polymerase chain reaction, and next-generation sequencing and are delivered through methods including microinjection, nanoliposomal delivery, viral vectors, and electroporation. The key applications include gene expression studies, molecular diagnostics, drug discovery and development, and cancer research, while the end-users include biotechnology companies, pharmaceutical companies, academic and research institutes, diagnostic laboratories, and contract research organizations.

Tariffs are influencing the ribonucleic acid (RNA) probes market by increasing the cost of imported labeled reagents, synthesis materials, and advanced detection instruments used in molecular diagnostics and research applications. This is affecting biotechnology companies, diagnostic laboratories, and academic research institutes, particularly in regions that depend on imported probe synthesis technologies, such as Asia-Pacific and Latin America. High-precision segments, including fluorescent and radiolabeled probes, are experiencing the greatest impact because of their reliance on specialized isotopes, enzymes, and imaging systems sourced globally. However, tariffs are encouraging local reagent manufacturing, strengthening regional supply chains, and increasing investment in domestic probe synthesis capabilities, thereby improving long-term market resilience and reducing import dependence.

The ribonucleic acid (rna) probe market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna) probe market statistics, including ribonucleic acid (rna) probe industry global market size, regional shares, competitors with a ribonucleic acid (rna) probe market share, detailed ribonucleic acid (rna) probe market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) probe industry. This ribonucleic acid (rna) probe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ribonucleic acid (RNA) probe market size has grown strongly in recent years. It will grow from $1.91 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to growth in molecular diagnostics and gene expression research, development of fluorescent and radiolabeled probe technologies, increasing adoption of in situ hybridization techniques, expansion of cancer genomics and infectious disease testing, rising demand for high specificity nucleic acid detection methods.

The ribonucleic acid (RNA) probe market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to integration of AI driven probe design and sequence optimization tools, increasing demand for precision diagnostics and personalized medicine, expansion of spatial transcriptomics and single cell analysis applications, rising adoption of multiplexed and high throughput probe based assays, growth in advanced imaging and molecular detection technologies. Major trends in the forecast period include integration of fluorescent multiplex rna probe technologies for high sensitivity gene expression detection, increasing adoption of custom synthesized rna probes for precision molecular diagnostics, growing use of isothermal amplification based probe detection systems, expansion of in situ hybridization techniques for spatial transcriptomics, rising demand for enzyme labeled probes in cancer and pathogen detection workflows.

The increasing prevalence of genetic disorders is expected to drive the growth of the ribonucleic acid (RNA) probe market going forward. Genetic disorders are diseases or conditions caused by alterations or mutations in an individual's DNA, which may be inherited from parents or arise spontaneously. The prevalence of genetic disorders is increasing due to advancements in diagnostic technologies and the expansion of genetic screening programs, enabling the identification of cases that previously remained undiagnosed. Ribonucleic acid (RNA) probes support the detection of genetic disorders by specifically binding to complementary messenger RNA sequences, allowing the identification of abnormal gene expression and genetic mutations for precise molecular diagnosis. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, cystic fibrosis patient registrations rose from 11,148 in 2022 and 11,318 in 2023 to 11,381 in 2024, reflecting consistent year-over-year growth. Therefore, the increasing prevalence of genetic disorders is driving the growth of the ribonucleic acid (RNA) probe market.

Major companies operating in the ribonucleic acid (RNA) probe market are emphasizing the development of innovative technologies, such as high-fidelity RNA synthesis enzymes, to improve probe quality, minimize immunogenic byproducts, and enhance accuracy in molecular diagnostics and research applications. High-fidelity RNA synthesis systems are advanced molecular biology technologies designed to produce RNA molecules with greater purity and significantly lower double-stranded RNA (dsRNA) contamination, which can otherwise induce unwanted immune responses and compromise assay reliability compared to conventional RNA polymerase-based synthesis methods. For instance, in September 2024, TriLink BioTechnologies Inc., a US-based Maravai LifeSciences company, in collaboration with Alphazyme LLC, a US-based biotechnology company, introduced CleanScribe RNA Polymerase, an advanced enzyme developed to substantially enhance RNA synthesis quality. The enzyme decreases double-stranded RNA formation by up to 85% during in vitro transcription, improving the safety and performance of RNA-based applications, including RNA probe production and mRNA construct development. Furthermore, the system integrates easily into existing IVT workflows without requiring significant protocol modifications, making it well suited for both research and therapeutic RNA manufacturing pipelines. The technology also enables improved reproducibility and higher-quality RNA production, supporting more dependable downstream diagnostic and genomic applications.

In May 2024, Bruker Corporation, a US-based technology company, acquired the NanoString Technologies Inc. business for $392.6 million. Through this acquisition, Bruker sought to enhance its spatial biology and life sciences tools portfolio by incorporating NanoString's gene expression profiling and spatial transcriptomics platforms, thereby broadening its capabilities in advanced biological research, translational science, and multi-omics discovery workflows across academic and clinical research markets. NanoString Technologies Inc. is a US-based life sciences tools company specializing in target-specific hybridization probes for the detection and quantification of ribonucleic acid (RNA).

Major companies operating in the ribonucleic acid (RNA) probe market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Revvity Inc., QIAGEN N.V., Bio-Techne Corporation, GenScript Biotech Corporation, Takara Bio Inc., RiboBio Co. Ltd., Bio-Synthesis Inc., Biotage AB, Biolegio B.V., Ella Biotech GmbH, Baseclick GmbH, Geno Technology Inc., Enzo Biochem Inc., LGC Biosearch Technologies, Integrated DNA Technologies (IDT)

North America was the dominating region in the ribonucleic acid (RNA) probe market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) probe market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA) probe market consists of sales of fluorescent RNA probes, gene expression detection probes, and pathogen detection RNA probes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid (RNA) Probe Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ribonucleic acid (rna) probe market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid (rna) probe ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna) probe market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Labeled Ribonucleic Acid Probes; Radiolabeled Ribonucleic Acid Probes; Biotinylated Ribonucleic Acid Probes; Digoxigenin Labeled Ribonucleic Acid Probes; Chemiluminescent Ribonucleic Acid Probes; Custom Or Synthesized Ribonucleic Acid Probes
• 2) By Technology: In Situ Hybridization; Fluorescence In Situ Hybridization; Polymerase Chain Reaction; Next Generation Sequencing
• 3) By Delivery Method: Microinjection; Nanoliposomal Delivery; Viral Vectors; Electroporation
• 4) By Application: Gene Expression Studies; Molecular Diagnostics; Drug Discovery And Development; Cancer Research
• 5) By End User: Biotechnology Companies; Pharmaceutical Companies; Academic And Research Institutes; Diagnostic Laboratories; Contract Research Organizations
• Subsegments:
• 1) By Labeled Ribonucleic Acid Probes: Fluorescent Labeled Ribonucleic Acid Probes; Enzyme Labeled Ribonucleic Acid Probes; Hapten Labeled Ribonucleic Acid Probes; Radioisotope Labeled Ribonucleic Acid Probes; Multiplex Or Dual Labeled Ribonucleic Acid Probes
• 2) By Radiolabeled Ribonucleic Acid Probes: Phosphorus Thirty Two Labeled Probes; Sulfur Thirty Five Labeled Probes; Tritium Labeled Probes; Iodine One Hundred Twenty Five Labeled Probes; Single End Or Internally Radiolabeled Probes
• 3) By Biotinylated Ribonucleic Acid Probes: Single Biotin Labeled Probes; Multiple Biotin Labeled Probes; Terminal Biotin Labeled Probes; Internal Biotin Labeled Probes; Streptavidin Based Detection Format Probes
• 4) By Digoxigenin Labeled Ribonucleic Acid Probes: Single Digoxigenin Labeled Probes; Dual Digoxigenin Labeled Probes; Terminal Digoxigenin Modified Probes; Internal Digoxigenin Incorporated Probes; Anti Digoxigenin Antibody Detection Based Probes
• 5) By Chemiluminescent Ribonucleic Acid Probes: Horseradish Peroxidase Based Chemiluminescent Probes; Alkaline Phosphatase Based Probes; Luminol Based Detection Probes; Chlorophenolred Beta D Galactopyranoside Or Chlorophenolred Beta D Galactopyranoside Star Substrate Based Probes; Direct Or Amplified Chemiluminescent Signal Probes
• 6) By Custom Or Synthesized Ribonucleic Acid Probes: In Vitro Transcription Derived Ribonucleic Acid Probes; Synthetic Oligonucleotide Ribonucleic Acid Probes; Polymerase Chain Reaction Generated Ribonucleic Acid Probes; Full Length Or Fragment Ribonucleic Acid Probes; Application Specific Probes
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corporation; Eurofins Scientific SE; Agilent Technologies Inc.; Revvity Inc.; QIAGEN N.V.; Bio-Techne Corporation; GenScript Biotech Corporation; Takara Bio Inc.; RiboBio Co. Ltd.; Bio-Synthesis Inc.; Biotage AB; Biolegio B.V.; Ella Biotech GmbH; Baseclick GmbH; Geno Technology Inc.; Enzo Biochem Inc.; LGC Biosearch Technologies; Integrated DNA Technologies (IDT)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.